Lucretia Myers, NP
Acute Care · Greenville, SCNPI 1134220932
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 266 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 15.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $2,128 and has fallen 95.3% since, to $99 in 2025.
Across 266 payments — averaging $19.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$765
- GSK$566
- Boehringer Ingelheim$512
- United Therapeutics Corporation$400
- Sanofi$362
- Actelion Pharmaceuticals US, Inc.$339
- plus $2K from 24 others
What the payments were for
- Food & beverage$5,06299%
- Education$331%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 44 | $765 |
| GSK | 40 | $566 |
| Boehringer Ingelheim | 25 | $512 |
| United Therapeutics Corporation | 19 | $400 |
| Sanofi | 16 | $362 |
| Actelion Pharmaceuticals US, Inc. | 18 | $339 |
| Regeneron Healthcare Solutions, Inc. | 14 | $323 |
| ANI Pharmaceuticals, Inc. | 7 | $212 |
| Philips North America LLC | 8 | $181 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $181 |
| Mylan Specialty L.p. | 9 | $178 |
| Bayer | 7 | $142 |
| Mallinckrodt Hospital Products Inc. | 5 | $125 |
| Genentech USA, Inc. | 6 | $112 |
| Insmed, Inc. | 8 | $111 |
| Amgen | 6 | $99 |
| Inspire Medical Systems, Inc. | 5 | $93 |
| Gilead | 3 | $71 |
| Johnson & Johnson | 5 | $65 |
| Idorsia Pharmaceuticals US Inc | 3 | $44 |
| Abiomed | 1 | $31 |
| Shionogi Inc | 1 | $30 |
| Hospira, Inc. | 1 | $26 |
| Pulmonx Corporation | 1 | $24 |
| Noctrix Health, Inc. | 1 | $23 |
| La Jolla Pharmaceutical Company | 1 | $18 |
| AbbVie | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Resmed Corp | 1 | $14 |
| Grifols USA, LLC | 1 | $14 |
How this compares
$5,095 in reported general payments places this provider in the 85th percentile of 339 acute care providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 568 | $504,388 |
| Breo ElliptaFluticasone/Vilanterol | 298 | $171,741 |
| Dupixent PenDupilumab | 21 | $80,304 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 99 | $79,336 |
| Spiriva RespimatTiotropium Bromide | 80 | $76,708 |
| SymbicortBudesonide/Formoterol Fumarate | 167 | $63,003 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 114 | $61,582 |
| NucalaMepolizumab | 14 | $51,077 |
| ZyfloZileuton | 12 | $43,181 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 56 | $42,047 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 1,023 | $37,910 |
| Advair HfaFluticasone Propion/Salmeterol | 36 | $26,183 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 156 | $25,528 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 30 | $18,226 |
| Spiriva HandihalerTiotropium Bromide | 12 | $17,816 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Nucala, Arnuity Ellipta | $566 | $813,9691,060 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat, Combivent Respimat | $512 | $174,271209 claims |
| AstraZenecaSymbicort, Breztri Aerosphere, Bevespi Aerosphere | $765 | $120,361246 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 339 acute care providers in South Carolina.
Other acute care in Greenville
- Heather BowersGreenville$94K
- Sarah MatthewsGreenville$28K
- Susan FunkGreenville$11K
- Jeffrey CobbGreenville$8K
- Jamez FletcherGreenville$7K
- Serena KocourekGreenville$7K
- Taylor NewtonGreenville$6K
- Cheryl MartinezGreenville$6K
- Stephanie RodriguezGreenville$6K
- Jessica SentellGreenville$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.